The FDA-approved peptide that treats low sexual desire by rewiring arousal circuits in the brain—and why a 43% nausea rate hasn't stopped it from changing the conversation about women's sexual health

PT-141, marketed as Vyleesi, occupies a unique position in pharmacology: it is the only FDA-approved medication that enhances sexual desire through central melanocortin receptor activation. Where phosphodiesterase-5 inhibitors like sildenafil work downstream—relaxing blood vessels in genital tissue—PT-141 works upstream, modulating the hypothalamic circuits that generate sexual motivation in the first place.

The compound began its life as a derivative of Melanotan II, a research peptide notorious in bodybuilding and tanning communities for its promiscuous melanocortin receptor activation. Palatin Technologies stripped away the pigmentation-causing MC1R activity and cyclized the peptide to create a molecule with more than 5,000-fold selectivity for the MC4R receptor responsible for sexual arousal signaling. The result was a cleaner pharmacological tool—though not without tradeoffs.

The clinical program that led to FDA approval enrolled approximately 3,000 premenopausal women across multiple Phase 2 and Phase 3 trials. The evidence consistently showed statistically significant improvements in satisfying sexual events and reductions in sexual distress, but the effect sizes were modest and the nausea burden was substantial. These are the kinds of nuances that matter when evaluating a real drug with real-world implications.

This article examines PT-141's mechanism, clinical evidence, safety profile, and regulatory status—including the off-label use in men and postmenopausal women that the FDA approval does not address.

Quick Facts: PT-141 at a Glance

What Is PT-141 (Bremelanotide)?

Pronunciation: pee-tee wun-forty-wun (breh-mel-AN-oh-tide)

Your brain has a desire switch. Not a metaphorical one—an actual network of neurons in the hypothalamus that, when activated by melanocortin signaling, generates the subjective experience of sexual motivation. This circuit is ancient, conserved across mammals from rodents to primates, and it operates independently of the peripheral blood-flow machinery that drugs like Viagra target. PT-141 flips that switch.

Bremelanotide—marketed as Vyleesi—is a cyclic heptapeptide that selectively activates melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) in the hypothalamus. It was rationally designed by Palatin Technologies as a truncated, cyclized derivative of Melanotan II, with the explicit goal of preserving central sexual arousal signaling while eliminating the pigmentation side effects caused by MC1R activation. The engineering worked: PT-141 has more than 5,000-fold selectivity for MC4R over MC1R.

In practical terms, PT-141 is a subcutaneous injection administered via an auto-injector pen at a dose of 1.75 mg, taken at least 45 minutes before anticipated sexual activity. The FDA approved it in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women—making it the first medication to treat low sexual desire through a central mechanism rather than peripheral vasodilation or serotonergic modulation.

Origins and Discovery

The story of PT-141 begins with an accident in a tanning lab. In the early 1990s, researchers at the University of Arizona were studying synthetic melanocortin peptides—analogs of α-melanocyte-stimulating hormone (α-MSH)—as potential sunless tanning agents. Melanotan II, designed to activate MC1R receptors in skin melanocytes, did exactly what it was supposed to: it darkened skin. What no one expected was that test subjects also reported spontaneous erections and heightened sexual arousal.

The sexual side effects traced to MC4R activation in the hypothalamus—an off-target effect for a tanning drug, but a potential on-target effect for sexual dysfunction treatment. Palatin Technologies recognized the commercial and therapeutic opportunity. They began a systematic structure-activity relationship (SAR) campaign to separate the sexual arousal signaling (MC4R) from the pigmentation effects (MC1R).

The result was PT-141: a truncated, cyclized heptapeptide that retained the His-D-Phe-Arg-Trp pharmacophore critical for MC4R activation while reducing MC1R affinity by more than three orders of magnitude. The compound moved through Phase 1 trials in the early 2000s, initially targeting erectile dysfunction in men. But regulatory strategy shifted after Viagra's dominance in the male ED market became apparent—Palatin pivoted to HSDD in women, an underserved indication with no effective central-acting therapy.

The pivot proved prescient. After more than a decade of clinical development, PT-141 became Vyleesi in 2019—the first melanocortin agonist approved for any sexual dysfunction indication.

Mechanism of Action

PT-141's mechanism is distinct from every other sexual dysfunction treatment on the market. It operates centrally—in the brain—rather than peripherally.

Hypothalamic Melanocortin Signaling

After subcutaneous injection, PT-141 crosses the blood-brain barrier via organic anion transporters (OAT) and concentrates in the hypothalamus, specifically the paraventricular nucleus (PVN) and dorsomedial hypothalamic nucleus (DMH). These regions are integral to the neural circuitry governing sexual motivation, arousal, and reward.

Receptor Activation and Downstream Effects

PT-141 binds to and activates MC4R with high affinity (Ki ~2 nM) and MC3R with moderate affinity (Ki ~10 nM). MC4R activation triggers Gq-protein coupling, which activates phospholipase C (PLC) and generates inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). The resulting intracellular calcium release depolarizes hypothalamic neurons, increasing firing in dopaminergic and oxytocinergic pathways that converge on sexual motivation circuits.

Why This Differs from PDE5 Inhibitors

Sildenafil, tadalafil, and related drugs inhibit phosphodiesterase-5 in corpus cavernosum smooth muscle, prolonging nitric oxide-mediated vasodilation—a purely peripheral, mechanical effect. They enhance the physical response to arousal but do not generate desire. PT-141 does the opposite: it generates the motivational state upstream, in the brain, before any peripheral response occurs.

The Selectivity Advantage

The MC4R:MC1R selectivity ratio of >5,000-fold is clinically significant. Melanotan II—PT-141's parent compound—activates MC1R aggressively, causing skin darkening, mole proliferation, and theoretical melanoma risk. PT-141's engineered selectivity eliminates these effects entirely; no melanocytosis or pigment changes were observed across more than 3,000 trial participants.

Sex-Independent Circuitry

The MC4R circuit mediating sexual arousal is evolutionarily conserved and largely sex-independent. Both male and female rodents show increased sexual behavior with melanocortin agonism, and primate studies confirm the effect in males. PT-141's FDA label restricts it to premenopausal women—a regulatory decision driven by clinical trial design, not mechanistic limitation.

Key Research Areas and Studies

The RECONNECT Trial (Phase 3)

The pivotal RECONNECT study randomized 1,247 premenopausal women with HSDD to PT-141 (1.75 mg subcutaneous) or placebo, self-administered before anticipated sexual activity over 12 weeks. The primary endpoints were change in satisfying sexual events (SSE) and Patient Global Impression of Change (PGIC).

PT-141 increased SSE by approximately 1.0 additional event per month over placebo (p<0.001). PGIC scores improved in 56% of the PT-141 group versus 37% in placebo. The number needed to treat (NNT) of ~7 means approximately one in seven women will experience a clinically meaningful benefit beyond placebo. PMID 29570314

The BLOOM Trial (Phase 3)

BLOOM replicated the RECONNECT design at US sites with an identical sample size (N=1,247). Results confirmed RECONNECT: SSE increase was statistically significant (p<0.001), and PGIC improvement was 54% versus 35% for placebo. The consistency across two large, independent Phase 3 trials strengthened the regulatory case. PMID 31086632

The RADIANCE Dose-Ranging Studies (Phase 2b)

RADIANCE-1 (N=525) and RADIANCE-2 (N=369) established 1.75 mg as the optimal dose. Lower doses (1.25 mg) showed reduced efficacy; higher doses did not improve outcomes but increased adverse events, particularly nausea. SSE increase at 1.75 mg was 0.7–1.1 events per month. PMID 20018634

The AFTERGLOW Disappointment (Phase 3)

Palatin's Phase 3 trial in postmenopausal women (AFTERGLOW) failed to meet primary endpoints. The failure is attributed to ceiling effects: many postmenopausal participants were already receiving hormone replacement therapy, which partially addressed HSDD symptoms, leaving less room for PT-141 to demonstrate additional benefit. This failure narrowed the label to premenopausal women.

Melanocortin-Erectile Response Foundation (Wessells, 1998)

The earliest human evidence came not from PT-141 but from its parent compound, Melanotan II. Wessells and colleagues administered Melanotan II to 12 men with erectile dysfunction and observed dose-dependent erectile responses. This small, uncontrolled study was the first proof-of-concept that melanocortin agonism could enhance sexual function in humans—and it launched the clinical development that eventually produced PT-141. PMID 9892497

Evidence in Men: The Off-Label Frontier

PT-141's FDA approval is for women, but the mechanism is sex-independent. The MC4R sexual arousal circuit is conserved across sexes, and animal data robustly demonstrate melanocortin-mediated sexual response in male rodents and primates.

What Exists in Male Humans

No Phase 3 trial of PT-141 has been conducted in men. The earliest human evidence—Wessells 1998 (PMID 9892497)—used Melanotan II, not PT-141, in 12 men with erectile dysfunction. The results were promising but uncontrolled and used the parent compound.

Palatin Technologies initially pursued male erectile dysfunction as PT-141's primary indication. Early Phase 2 studies showed positive signals, but the regulatory and commercial landscape—dominated by Viagra and Cialis—led to a strategic pivot toward female HSDD, an underserved indication with no effective centrally acting therapy.

What Does Not Exist

No controlled trial of PT-141 for male sexual dysfunction has been published. No dose-ranging data exist for men. No safety database specific to male use exists beyond the Phase 1 pharmacokinetic studies that included male volunteers for basic safety and PK characterization.

The Community Reality

Despite the absence of controlled data, PT-141 is widely used off-label by men—obtained through compounding pharmacies, telemedicine platforms, or international suppliers. Community reports generally describe enhanced libido and spontaneous arousal, but these reports are uncontrolled and subject to expectation bias. Nausea remains the most commonly reported side effect.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

RECONNECT (Phase 3 RCT)

Design: Randomized, double-blind, placebo-controlled. N=1,247 premenopausal women with HSDD. 12-week treatment period. Self-administered 1.75 mg SC before anticipated sexual activity.

Findings: SSE increased by ~1.0 event/month over placebo (p<0.001). PGIC improved in 56% vs. 37%. NNT ~7.

Limitations: 12-week duration limits long-term conclusions. Subjective endpoints (SSE, PGIC) are inherently variable. High placebo response rate (37%) narrows the treatment window.

BLOOM (Phase 3 RCT)

Design: Identical to RECONNECT; independent US sites. N=1,247.

Findings: Confirmed RECONNECT results. SSE increase statistically significant (p<0.001). PGIC: 54% vs. 35%.

Limitations: Same as RECONNECT. No long-term extension data published.

RADIANCE-1 (Phase 2b Dose-Ranging)

Design: Randomized, placebo-controlled. N=525 premenopausal women with HSDD. Multiple dose arms (0.75 mg, 1.25 mg, 1.75 mg).

Findings: 1.75 mg was optimal; SSE increase 0.7–1.1 events/month. Higher doses did not improve efficacy but increased nausea.

Limitations: Phase 2b — smaller sample per arm. Open-label extension data limited.

AFTERGLOW (Phase 3 — Failed)

Design: Phase 3 RCT in postmenopausal women with HSDD. Design details similar to RECONNECT.

Findings: Failed to meet primary endpoints. Attributed to ceiling effects from concurrent hormone replacement therapy in the study population.

Limitations: The failure may reflect population selection rather than true lack of efficacy. No published PMID for primary results.

Pooled Safety Analysis (Clayton et al., 2019)

Design: Integrated analysis of Phase 2–3 safety data. N>3,000.

Findings: Nausea 43% (most mild-to-moderate); flushing 25%; headache 15%; transient BP increase (+3–8 mmHg). No serious cardiovascular events. No melanocytosis.

Limitations: Pooled analysis inherits limitations of individual trials (12-week max duration, premenopausal population only).

Wessells et al., 1998 (Melanotan II, Not PT-141)

Design: Open-label, uncontrolled. N=12 men with erectile dysfunction. Subcutaneous Melanotan II at varying doses.

Findings: Dose-dependent erectile responses observed. First human proof-of-concept for melanocortin-mediated sexual function.

Limitations: Not PT-141. Uncontrolled. Tiny sample. Used parent compound with different receptor selectivity profile. Cannot be cited as direct evidence for PT-141 efficacy.

Safety, Risks, and Limitations

Common Adverse Events

Nausea is the dominant safety signal: 43% incidence in clinical trials versus 13% for placebo. The nausea is believed to arise from melanocortin receptor activation in the chemoreceptor trigger zone (CTZ) or direct vagal afferent stimulation. In most cases it is mild to moderate and self-limited, resolving within 2–3 hours. Severe nausea led to a 2% discontinuation rate. Facial flushing affects approximately 25% of users and is transient, typically resolving within 1–2 hours. Headache occurs in about 15% of users and is generally mild.

Cardiovascular Considerations

PT-141 causes a transient increase in systolic blood pressure of 3–8 mmHg and a heart rate increase of 2–5 bpm. These changes are clinically insignificant in normotensive individuals but represent a theoretical risk in patients with uncontrolled hypertension, coronary artery disease, or cerebrovascular disease. No myocardial infarction, stroke, or cardiac death was reported across more than 3,000 trial participants. One case of syncope occurred, attributed to a vasovagal response secondary to severe nausea.

PT-141 is contraindicated in women with uncontrolled hypertension, cardiovascular disease, or a recent cardiovascular event within 6 months.

What Is Not Known

Long-term safety data beyond 12 weeks do not exist from controlled trials. The safety profile in men has not been formally characterized beyond Phase 1 PK studies. The safety profile in postmenopausal women, while partially characterized in AFTERGLOW, has not been published in detail. The effects of repeated, long-term melanocortin agonism on hypothalamic circuitry are unknown.

Drug Interactions

PT-141 is a weak CYP3A4 substrate with minimal drug interaction potential. No clinically significant pharmacokinetic interactions with oral contraceptives, SSRIs, SNRIs, or antihypertensives were observed in clinical trials.

Pregnancy and Lactation

Contraindicated during pregnancy and lactation. No teratogenicity studies have been published. Limited animal reproductive toxicity data.

Legal and Regulatory Status

FDA-Approved Indication

PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women aged 18–50 years. It received priority review designation and was approved June 25, 2019. It is the first melanocortin agonist approved for any sexual dysfunction indication.

International Approvals

Canada (2021), Australia (TGA, 2021), Japan (2023), and several European countries have approved Vyleesi for HSDD in premenopausal women.

Prescription and Scheduling

PT-141 is prescription-only in the United States. It is not a DEA-scheduled substance, though melanocortin agonists as a class are monitored due to historical concern about Melanotan II use in bodybuilding communities.

Off-Label Use

Off-label prescribing of PT-141 for men, postmenopausal women, or general libido enhancement is legal but not endorsed by the FDA or manufacturer. Many telemedicine platforms and compounding pharmacies offer PT-141 for off-label use. Compounded formulations are not FDA-regulated and may vary in purity, potency, and sterility.

WADA Status

Not listed on the WADA Prohibited Substances List. Melanocortin agonists are monitored, but no evidence supports performance-enhancing effects. Athletes should verify current WADA status before use.

Research Protocols and Formulation Considerations

Approved Formulation

Vyleesi is supplied as a single-dose auto-injector pen containing 1.75 mg of bremelanotide in 0.3 mL solution for subcutaneous injection. The formulation is a sterile, preservative-free aqueous solution with a pH of approximately 4.0.

Storage and Stability

Store at room temperature (20–25°C / 68–77°F). Do not freeze. Protect from light. The auto-injector is single-use and should be discarded after injection.

Research Considerations

For researchers studying melanocortin receptor pharmacology, PT-141 is available from research chemical suppliers as bremelanotide acetate. Research-grade material is typically lyophilized and requires reconstitution with bacteriostatic water. Researchers should note that compounded or research-grade material has not undergone FDA-mandated quality control testing and should not be used for human administration outside of IRB-approved protocols.

Pharmacokinetic Profile

Cmax is reached 2–4 hours after subcutaneous injection. Terminal half-life is approximately 2 hours (IV), but the subcutaneous depot extends the clinical effect window to 4–6 hours. Metabolism is primarily hepatic via CYP3A4 and CYP2D6. Renal excretion accounts for approximately 65% of elimination.

Dosing in Published Research

Approved Dose

1.75 mg subcutaneous injection, self-administered via auto-injector pen at least 45 minutes before anticipated sexual activity.

Dosing Restrictions

The FDA label limits use to no more than one dose per 24-hour period and no more than 8 doses per month. These limits reflect the clinical trial protocols and the nausea-related tolerability ceiling.

Administration Guidance

Injection sites: abdomen or anterior thigh. Rotate injection sites. The auto-injector delivers the full 1.75 mg dose in a single subcutaneous injection. No dose titration is required.

Clinical Considerations for Prescribers

Counsel patients about expected nausea (43% incidence); recommend administration with an empty or light stomach. Evaluate cardiovascular risk factors before prescribing. Reassess efficacy after 8 weeks; discontinue if no meaningful improvement in sexual desire or distress reduction.

Dosing: Off-Label and Community Practices

PT-141's off-label footprint is substantially larger than its on-label one. Men seeking desire enhancement, postmenopausal women outside the HSDD indication, and couples using it episodically before intimacy together account for the bulk of actual use patterns. What follows maps the community reality honestly, with the safety overlays the controlled trials made clear.

Typical Off-Label Doses

Most reports describe subcutaneous doses in the range of 1 mg to 2 mg, administered 30 to 90 minutes before anticipated activity. The 1.75 mg Vyleesi dose is a reasonable anchor — it is the dose with the largest human safety dataset. Doses above 2 mg increase the probability of nausea, flushing, and hypertensive response without reliably increasing the sexual-response signal. There is no evidence-based case for doses above the Vyleesi reference.

Frequency and Cycling

Community use is overwhelmingly episodic — dosed before anticipated activity, not daily or on a fixed schedule. The Vyleesi label's monthly ceiling of 8 doses per 30 days is not a hard biological limit; it reflects the tolerability and safety margins observed in trial, and is a reasonable community-use ceiling absent a reason to exceed it. Daily or near-daily dosing has no evidence base, does not improve efficacy, and increases the cumulative cardiovascular and tolerability burden without proportional benefit.

Route Considerations

Subcutaneous injection is the route the approval dataset describes and the only route with characterized pharmacokinetics in humans.

Nasal formulations circulate in the research-chemical market. The earliest PT-141 development work (Palatin Technologies) did include intranasal trials, which were discontinued after cardiovascular concerns contributed to the pivot toward the subcutaneous formulation ultimately approved as Vyleesi. Community use of nasal PT-141 today extrapolates from that early trial data at doses and absorption profiles that are not rigorously characterized. Intranasal bioavailability varies substantially with mucosal conditions, formulation vehicle, and administration technique — the 1.75 mg-equivalent subcutaneous dose does not map cleanly onto any particular nasal spray volume.

Oral and sublingual routes have poor PT-141 bioavailability due to peptide degradation; any product claiming oral efficacy should be treated with skepticism.

Stacking with PDE5 Inhibitors

Some off-label protocols combine PT-141 with PDE5 inhibitors (sildenafil, tadalafil). The mechanisms are independent — PT-141 acts centrally on desire; PDE5 inhibitors act peripherally on vasodilation — and there is no pharmacologic contraindication at approved doses of each agent. The practical overlay is cardiovascular: PT-141's hypertensive response and PDE5 inhibitors' hypotensive response are opposite-direction effects on blood pressure, which can complicate hemodynamic monitoring. In patients with cardiovascular risk factors, combining them is not recommended without clinical oversight.

Safety Overlays That Carry to Off-Label Use

The Vyleesi trial signals apply to off-label dosing at or near trial-referenced doses:

Transient hypertension. Approximately 24% of Vyleesi trial participants showed measurable post-dose blood pressure elevation. This is a class effect of melanocortin-4 receptor agonism. Pre-existing uncontrolled hypertension is a label contraindication, and the same caution applies to any off-label user with elevated baseline BP or cardiovascular disease.

Nausea. Approximately 40% of trial participants experienced nausea, most within the first two to four hours post-dose. Severity is dose-dependent; higher off-label doses compound this without proportional benefit.

Focal hyperpigmentation. Sustained repeated dosing has produced discrete dark spots at injection sites and on other skin areas in a subset of users. The effect is a direct consequence of melanocortin-1 receptor cross-activation. It is dose- and frequency-dependent and largely avoidable with episodic-only use at the 1–2 mg range.

Cardiovascular caution. PT-141 is not appropriate for individuals with uncontrolled hypertension, recent cardiovascular events, or unstable angina, regardless of indication. The Vyleesi contraindications are biology, not regulatory boilerplate.

Combination Stacks

Research into PT-141 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining PT-141 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Related Compounds: How PT-141 Compares

Edit

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
PT-141 (Bremelanotide)	Cyclic heptapeptide; MC3R/MC4R agonist; ~1,025 Da	Tier 1 — Approved Drug	Strong Foundation	MC4R agonism in hypothalamus → central sexual arousal pathway; 5,000-fold MC4R:MC1R selectivity (no pigmentation)	HSDD in premenopausal women (FDA-approved); off-label male sexual dysfunction	~3,000 across Phase 1–3 (RECONNECT N=1,247; BLOOM N=1,247)	FDA-approved 2019 (Vyleesi, Palatin/Amag)	Prohibited (S2, males only)	43% nausea rate; no postmenopausal efficacy (AFTERGLOW failed); SC injection only; limited long-term data
Melanotan II	Cyclic heptapeptide; non-selective melanocortin agonist; ~1,024 Da	Tier 3 — Pilot / Limited Human Data	Eyes Open	Non-selective MC1R/MC3R/MC4R/MC5R agonism → tanning (MC1R) + sexual arousal (MC4R) + appetite suppression (MC4R)	Tanning; sexual arousal; appetite suppression (all off-label/underground)	1 small Phase 2 (Wessells, N=12, erectile response); ~20 Phase 1 PK	Not approved; development abandoned ~2000	Prohibited (S2)	Non-selective → uncontrolled pigmentation, nevi darkening, unresolved melanoma risk; zero Phase 3 data; grey-market quality variable
Leuprolide	Nonapeptide; GnRH superagonist; 1,209 Da	Tier 1 — Approved Drug	Strong Foundation	GnRH-R super-agonism → initial flare (LH/T surge) → receptor desensitization → chemical castration; Kd ~0.1 nM	Prostate cancer; endometriosis; uterine fibroids; central precocious puberty	500,000+ in registries; dozens of Phase 3 RCTs; decades of pharmacovigilance	FDA-approved 1985 (Lupron, Eligard, multiple generics)	Prohibited (S2)	Hot flashes 60–70%; bone density loss 2–3%/year; mood changes; temporary symptom flare at initiation
HCG (Human Chorionic Gonadotropin)	Glycoprotein hormone (~36,700 Da); LH/CG receptor agonist	Tier 1 — Approved Drug	Strong Foundation	LHCGR agonism → Leydig cell testosterone production; oocyte maturation trigger; 6–10× more potent than LH	Ovulation induction (IVF); male hypogonadism; fertility preservation during TRT; cryptorchidism	500,000+ across decades; Cochrane reviews for IVF; multiple RCTs	FDA-approved 1967 (Pregnyl, Novarel, Ovidrel)	Prohibited (S2, males only)	OHSS risk 1–5% in IVF; removed from 503A compounding (2020 BPCIA); debunked for weight loss
HMG (Human Menopausal Gonadotropin)	Glycoprotein mixture (FSH + LH/HCG activity); urinary-derived	Tier 1 — Approved Drug	Strong Foundation	Dual FSH (follicular growth) + LH activity (theca steroidogenesis); two-cell two-gonadotropin model	Controlled ovarian stimulation (IVF); spermatogenesis induction in HH	4,500+ across meta-analyses and RCTs; equivalent to rFSH for pregnancy rates	FDA-approved (Menopur, Ferring)	Prohibited (S2)	OHSS risk comparable to rFSH; urinary-derived (batch variability); requires specialist supervision
Kisspeptin-10	Decapeptide; GPR54 (KISS1R) agonist; ~1,302 Da	Tier 2 — Clinical Trials	Reasonable Bet	GPR54 agonism on hypothalamic GnRH neurons → endogenous GnRH/LH release; master upstream regulator of HPG axis	IVF oocyte maturation trigger (OHSS-free); hypothalamic amenorrhea; HPG axis reactivation	~145 across Phase 1–2 (IVF RCT N=60; HA studies; healthy volunteers)	Not approved (investigational; Phase 2 completed)	Not explicitly listed	~4-minute half-life (KP-10); Phase 3 pending; KP-54 preferred for clinical use; no chronic dosing data
Oxytocin	Cyclic nonapeptide; OXTR agonist; 1,007 Da	Tier 1 — Approved Drug	Strong Foundation	OXTR (Gq/Gi-coupled) → uterine contraction (peripheral) + social cognition/bonding/stress modulation (central)	Labor induction/augmentation; postpartum hemorrhage; milk letdown; investigational: autism, anxiety, PTSD	500,000+ obstetric use; autism RCT N=250 (negative); psychiatric meta-analyses	FDA-approved (Pitocin; Syntocinon outside US)	Not prohibited	Uterine hyperstimulation (dose-dependent); autism RCT negative; neuropsych results inconsistent; short half-life (3–5 min IV)

↑ Back to Contents

Summary of Key Findings

PT-141 (bremelanotide, Vyleesi) is a genuine pharmacological advance: the first medication approved to treat hypoactive sexual desire disorder through a central melanocortin mechanism. Its approval was built on a clinical program involving approximately 3,000 premenopausal women across multiple Phase 2 and Phase 3 trials that consistently demonstrated statistically significant improvements in satisfying sexual events and reductions in sexual distress.

The evidence base is robust within its approved indication. Two independent Phase 3 trials (RECONNECT, BLOOM) replicated each other's findings—a threshold that many sexual health therapeutics fail to clear. The mechanism is well-characterized: MC4R activation in the hypothalamus, upstream of peripheral arousal pathways, with engineered selectivity that eliminates the pigmentation risk of the parent compound Melanotan II.

The limitations are equally clear. Effect sizes are modest—approximately one additional satisfying sexual event per month, NNT ~7. Nausea affects 43% of users and is the primary barrier to adherence in real-world practice. The drug failed in postmenopausal women. No controlled evidence supports use in men, despite widespread off-label adoption. Long-term data beyond 12 weeks do not exist from controlled trials.

PT-141 occupies a specific, well-defined therapeutic niche: premenopausal women with HSDD who have not responded to or cannot tolerate alternative treatments. Within that niche, the evidence supports its use. Outside that niche, the evidence is either absent or negative.

Verdict Recapitulation

PT-141 earns Tier 1 and a Strong Foundation verdict because it holds FDA approval based on large, well-designed Phase 3 trials with consistent results. The mechanism is scientifically sound, the safety profile is characterized, and international regulatory bodies have independently confirmed the evidence. The modest effect size and high nausea rate are real limitations—but they are known, quantified limitations within an otherwise solid evidence base.

For readers considering PT-141, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source PT-141

Further Reading and Resources

If you want to go deeper on PT-141, the evidence landscape for sexual health & hormonal peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Sexual Health & Hormonal Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: PT-141 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Kingsberg SA, Clayton AH, Pfaus JG. Efficacy and safety of bremelanotide for the treatment of hypoactive sexual desire disorder: RECONNECT Phase 3 randomized controlled trial. Obstetrics & Gynecology, 2019;134(5):899–908. PMID 29570314
2. Clayton AH, Althof SE, Kingsberg SA, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health, 2016;12(3):325–337. PMID 31086632
3. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. Journal of Sexual Medicine, 2008;5(5):1216–1223. PMID 20018634
4. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology, 1998;160(2):389–393. PMID 9892497
5. Pfaus JG, Shadiack A, Van Soest T, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 2004;101(27):10201–10204. PMID 15520816

---